Is Teladoc Health Stock a Buy After Its 77% Drop?

TL;DR

Teladoc Health's stock has plummeted over 77% in the past year, and following Q4 earnings, it fell an additional 5%. With guidance falling short of analyst expectations and the stock showing no signs of reversal in its current downtrend, buying the dip is risky. A thorough analysis of both technical indicators and valuation is essential before considering an investment.

Transcript

what is going on investors hopefully you guys are doing well out there it is time to talk about teledoc health ticker symbol tdoc over the last year i tell you what if you own this stock you probably had to make an appointment with your doctor because this stock is down over 77 and i'm seeing after reporting q4 earnings in the after hour stocks tra... Read More

Key Insights

• 🍝 Teledoc Health's stock has experienced a significant decline over the past year, making it important to approach with caution.
• 🥺 The company's Q4 earnings beat expectations on revenue but fell short on guidance, leading to a negative market reaction.
• 💪 Teledoc Health's revenue growth has been strong, but it has not been enough to support the stock's valuation.
• 😀 The company's expenses have started to decrease, but it still faces challenges related to stock-based compensation.
• 🤘 The stock's technical chart shows a clear downtrend, and there are no signs of reversal at the moment.
• 🥳 Teledoc Health's valuation based on price-to-sales ratio has become more attractive due to the stock's decline.
• 😀 The company's cash flows have improved, but it still faces challenges in terms of profitability.

Questions & Answers

Q: Why has Teledoc Health's stock price been declining?

Teledoc Health's stock has been declining due to a combination of factors, including disappointing earnings results, weak guidance, and the overall downtrend in the market for high-growth, unprofitable companies.

Q: What is the company's revenue growth like?

Teledoc Health has shown strong revenue growth, with the most recent quarter's revenue amounting to $554 million, a 44% increase compared to the previous year. However, this growth has not been sufficient to support the stock's valuation.

Q: How has Teledoc Health managed its expenses?

While Teledoc Health's expenses have historically been high, the most recent quarter saw a decrease in expenses, which is a positive sign. The company has been able to reduce operating losses, but it continues to struggle with stock-based compensation.

Q: What is the outlook for Teledoc Health's stock?

The stock's technical chart indicates a downtrend, and there are no current signs of reversal. The company's weak guidance and lack of profitability also make it a risky investment option. Investors should wait for the stock to show signs of stability and improvement before considering buying.

Summary & Key Takeaways

• Teledoc Health's stock has experienced a significant decline of over 77% in the past year, and Q4 earnings have resulted in an additional 5% drop in after-hours trading.

• The company's guidance for the upcoming quarter fell short of Wall Street estimates, which could negatively impact the stock's performance.

• From a technical perspective, the stock is currently in a downtrend with no signs of reversal, making it risky to buy the dip.